Children's Hospital of Philadelphia Awarded Up to $38.9M for Gene Editing Therapies

Children's Hospital of Philadelphia (CHOP) has secured a significant five-year award, potentially up to $38.9 million, from the Advanced Research Projects Agency for Health (ARPA-H). This funding will support the development of personalized gene editing therapies aimed at treating four groups of rare, liver-related genetic disorders.

The research, led by Dr. Rebecca Ahrens-Nicklas and Dr. Lindsey A. George at CHOP, will focus on creating a scalable platform for individualized gene editing approaches. The goal is to treat infants and children suffering from life-threatening conditions such as urea cycle disorders, organic acidemias, and bleeding or clotting disorders.

According to Dr. Ahrens-Nicklas, current standard care for these patients often involves lifelong special diets, regular infusions, or liver transplants, all of which carry significant risks and potential delays. "Formal clinical trials are needed to evaluate if gene editing therapies are safe and if they work," she stated, highlighting the need for more effective treatment options.

The five-year plan includes refining base editing and prime editing technologies using lipid nanoparticle systems. The initiative also encompasses conducting clinical trials, seeking regulatory approvals, and expanding access to these therapies by implementing them at community sites and remote hubs. The project builds upon previous work in personalized gene editing, including the treatment of a child with a rare genetic disorder.